M-A | Toxicity profiles of systemic therapies for advanced hepatocellular carcinoma.
26 Jul, 2022 | 12:34h | UTC
Commentary on Twitter
This meta-analysis of 30 high-quality RCTs in patients with advanced hepatocellular carcinoma found that immune checkpoint inhibitors were associated with similar liver toxicity but lower serious adverse events compared to tyrosine kinase inhibitors. https://t.co/i0gJg0bqdX
— JAMA Network Open (@JAMANetworkOpen) July 18, 2022